Citadel Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-28,400
| Closed | -$684K | – | 15739 |
|
|
2023
Q1 | $684K | Sell |
28,400
-32,200
| -53% | -$404K | ﹤0.01% | 7629 |
|
|
2022
Q4 | $641K | Buy |
60,600
+19,600
| +48% | +$158K | ﹤0.01% | 7729 |
|
|
2022
Q3 | $185K | Buy |
41,000
+4,100
| +11% | +$18.7K | ﹤0.01% | 10482 |
|
|
2022
Q2 | $148K | Sell |
36,900
-7,200
| -16% | -$34.1K | ﹤0.01% | 10999 |
|
|
2022
Q1 | $323K | Sell |
44,100
-14,600
| -25% | -$87.3K | ﹤0.01% | 10429 |
|
|
2021
Q4 | $330K | Sell |
58,700
-3,600
| -6% | -$22.9K | ﹤0.01% | 10721 |
|
|
2021
Q3 | $399K | Sell |
62,300
-125,000
| -67% | -$803K | ﹤0.01% | 10414 |
|
|
2021
Q2 | $1.58M | Buy |
187,300
+106,000
| +130% | +$855K | ﹤0.01% | 7199 |
|
|
2021
Q1 | $853K | Buy |
81,300
+31,700
| +64% | +$446K | ﹤0.01% | 8500 |
|
|
2020
Q4 | $840K | Buy |
49,600
+23,600
| +91% | +$354K | ﹤0.01% | 7160 |
|
|
2020
Q3 | $334K | Sell |
26,000
-10,800
| -29% | -$136K | ﹤0.01% | 7952 |
|
|
2020
Q2 | $519K | Buy |
36,800
+23,200
| +171% | +$293K | ﹤0.01% | 7007 |
|
|
2020
Q1 | $125K | Sell |
13,600
-3,500
| -20% | -$45.1K | ﹤0.01% | 8453 |
|
|
2019
Q4 | $255K | Buy |
+17,100
| New | +$152K | ﹤0.01% | 7836 |
|
Other funds holding PRVB
Citadel Advisors's PRVB Position: Q2 2023 in Review
Citadel Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 520,560 shares — an estimated $12.5M sold.
Citadel Advisors first reported a position in PRVB in Q1 2019 and held it in 13 quarters. The position peaked at $12.5M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Citadel Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 520,560 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $12.5M.
- Citadel Advisors first reported a position in Provention Bio, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
- Citadel Advisors's Provention Bio, Inc. Common Stock position peaked at $12.5M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.